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Abstract We have demonstrated for the first time that the 
reconstituted Sendai viral envelopes containing only the fusion 
protein (F-virosomes) are efficient vehicles for the delivery of 
foreign genes specifically into human hepatoblastoma cells 
(HepG2) in culture. The membrane fusion-mediated entry of 
CA T (chloramphenicol acetyl transferase) gene into the cells was 
confirmed and the amount delivered to various subcellular 
fractions was quantitated. The dose dependence and kinetics of 
expression of biologically active CAT protein in HepG2 cells was 
measured. The CAT expression level in F-virosome-mediated 
delivery was significantly higher than that of Lipofectin or 
liganded proteo-liposome-mediated gene transfer. This kind of 
targeted delivery by means of membrane fusion induced by viral 
envelope glycoprotein may have wide applications to various gene 
transfer strategies both in vitro and in vivo. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
A major problem in the delivery of DNA and other bio-
logical macromolecules into cells is the crossing of the perme-
ability barrier imposed by the plasma membrane. In the past 
few years, closed lipid bilayer vesicles (liposomes) have been 
used for delivering various macromolecules into living cells 
[1]. In this system the loaded liposomes are taken up by en-
docytosis and are released in lysosomes where low pH and 
various lysosomal enzymes inactivate the enclosed material 
[2]. Degradation of DNA in lysosomes is known to be one 
of the limiting factors in gene transfer by liposomes [3]. 
Although a recent study demonstrates the potential of cati-
onic liposomes to transfer and express a human gene in the 
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nasal epithelium of patients, the transfection efficiency and the 
duration of expression will need to be much improved from a 
wider therapeutic point of view [4]. Another delivery system is 
based on retroviral vectors either alone or in combination 
with cationic liposomes [5,6]. Although this mode has a higher 
transformation efficiency and exhibits stable transduction of 
non-dividing cells, the viral oncogene and the random inser-
tion of the retroviral genes into the host genome have unde-
sirable side effects besides inherent cytopathicity [7] and non-
specific targeting to normal cells [8]. Adenovirus based gene 
transfer vectors suffer from similar problems [9,10]. 
Reconstituted Sendai viral envelopes (F,HN-virosomes) 
containing two glycoproteins, F (fusion protein) and HN (he-
magglutinin-neuraminidase), are known to fuse efficiently with 
the plasma membrane of target cells and are excellent carriers 
for fusion-mediated microinjection of biologically active mac-
romolecules in vitro [11]. This delivery system utilizes the 
binding of HN to the sialic acid residues of the membrane, 
followed by the F-protein-mediated fusion of the viral enve-
lopes with the host cell plasma membrane at neutral pH. 
However, this promising system of gene delivery lacks cell 
type specificity because of the presence of HN protein, which 
is known to bind to various cell types through the sialic acid 
moiety of cell surface glycoconjugates. In spite of all recent 
developments in gene therapy since 1989, the formulation of a 
targeted gene delivery 'vector' is still far from ideal [8,12,13]. 
It has been recently demonstrated in our laboratory that F-
virosomes (devoid of HN protein) can specifically bind and 
fuse with HepG2 cells [14]. The target specificity of F-viro-
somes has been ensured by the strong interaction between the 
terminal (3-galactose moiety of F-protein and the asialoglyco-
protein receptor (ASGP-R) on the membrane of HepG2 cells 
[14]. In further studies, F-virosomes have been successfully 
used for the delivery of biologically active macromolecules 
into the cytoplasm of liver cells both in vitro and in vivo 
[15-17]. Liver is known to be a model organ for somatic 
gene therapy. Hence, F-virosomes by virtue of their specific 
interaction and fusion with liver cells should be an ideal vec-
tor for gene delivery both in vitro and in vivo [18]. We report 
for the first time the F-virosome-mediated delivery of CAT 
gene and its expression in HepG2 cells in a systematic and 
quantitative fashion. The efficacy of this system for targeted 
gene expression in HepG2 cells is discussed. 
2. Materials and methods 
2.1. Bacterial strains and plasmids 
E. coli strain DH5a was used for all transformation experiments. 
The plasmid pCIS2, containing the human cytomegalovirus (CMV) 
immediate early promoter-enhancer element, was obtained from Gen-
entech, Inc., USA. Plasmid pTKCAT, containing the thymidine kin-
ase promoter linked to the CAT gene was obtained from Dr. S.K. 
Goswami, State University of New York Health Science Center at 
Brooklyn, USA. 
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2.2. Virus, cells 
Sendai virus (Z strain) was grown, harvested, and purified following 
published protocols [14]. Viral yield was estimated in terms of protein 
and its activity was checked [14]. HepG2 cells and CHO (Chinese 
hamster ovary) cells were grown as described earlier [16]. 
2.3. Enzymes and chemicals 
Restriction enzymes and T4 DNA ligase were purchased from New 
England Biolabs Inc., USA. Random primers DNA labeling system, 
Dulbecco's modified Eagle's medium (DMEM), Dulbecco's phos-
phate-buffered saline (DPBS), fetal calf serum (FCS), trypsin-
EDTA, and Lipofectin® reagent were obtained from Life Technolo-
gies Inc., USA. CAT ELISA kit was purchased from Boehringer 
Mannheim, Germany. All other chemicals used were of the highest 
grade commercially available. 
2.4. Construction and isolation of eukaryotic expression vector, 
pCIS3CAT 
A 1.55 kb Xhol-Smal fragment from plasmid pTKCAT containing 
the CAT gene and SV40 polyadenylation signal was cloned into the 
plasmid pCIS2, downstream of the cytomegalovirus promoter-en-
hancer element. A putative clone was identified and confirmed by 
restriction mapping and Southern hybridization using 32P-labeled 
CAT gene fragment as a probe [19]. This putative clone was desig-
nated as pCIS3CAT. The plasmid pCIS3CAT was isolated by stand-
ard alkaline lysis method and purified on CsCl density gradients [19]. 
2.5. Preparation of F-virosomes loaded with pCIS3CAT DNA 
Reconstituted Sendai viral envelopes containing the F-protein (F-
virosomes) were prepared as described [14]. The Triton X-100 solubi-
lized fraction of virus was mixed with pCIS3CAT DNA (75 itg of 
DNA/mg of viral protein) and reconstituted by stepwise removal of 
detergent using SM2 biobeads. The unentrapped DNA adsorbed on 
outer surface of virosomal membrane was removed by treatment of 
virosomes with DNAase I (60 ug DNAase I/mg of F-protein) at 37°C 
for 30 min. The presence of entrapped DNA was checked by lysing 
virosomes with 2% SDS, loading on an 0.8% agarose gel, and sub-
sequently staining with ethidium bromide. The amount of pCIS3CAT 
DNA entrapped in F-virosomes was calculated using 32P-labeled 
DNA as a tracer. Structural integrity of loaded F-virosomes was 
checked for leakage of entrapped DNA during incubation with phos-
phate-buffered saline (PBS, 150 mM NaCl, 10 mM phosphate, pH 
7.4), with fresh mouse plasma and DMEM containing 10% FCS at 
37°C for 16 h and after heat-treatment at 56°C for 30 min. 
2.6. Fusion-mediated delivery of pCIS3CAT DNA to HepG2 cells and 
its quantitation in various subcellular fractions 
The pCIS3CAT DNA was labeled with [a-32P]dCTP by random 
primer labeling technique [19]. Monolayer cells (grown in T-25 flasks, 
1 X 107 cells) were washed thrice with 2 ml of DMEM without serum. 
Cells were incubated with loaded F-virosomes (0.3 mg of F-protein 
containing 1 ug of labeled DNA, in 2 ml of DMEM without serum) 
for 2 h at 37°C/5% C0 2 . HepG2 cells preincubated with 2 mg/ml 
asialofetuin, heat-treated F-virosomes and free DNA were used as 
controls. After 2 h of fusion, medium was replaced with DMEM 
containing serum (10% FCS) and cells were further incubated for 24 
h at 37°C/5% C0 2 . After 24 h, the cell surface bound (unfused) viro-
somes were removed by washing cells 4 times with 2 ml of ice-cold 
DPBS containing 5 mM EDTA [16]. After EDTA stripping, mono-
layer cells were lifted with 0.5 ml of trypsin-EDTA (0.05% trypsin, 
0.53 mM EDTA) and washed thrice with 1.5 ml of ice-cold Tris-
buffered saline (TBS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4). 
Finally, the cell pellet was resuspended in 1 ml of isotonic homoge-
nizing buffer (0.01 M Tris-HCl (pH 7.4) containing 0.25 M sucrose) 
and then dispersed in Potter-Elvehjem type homogeniser at 4°C for 
subcellular fractionation [16]. Plasmid DNA was extracted from each 
subcellular fraction in 1 M NaCl and 0.6% SDS according to Hirt 
lysis method [20]. DNA from each subcellular fraction was electro-
phoresed on 0.8% agarose gel and the bands corresponding to plasmid 
DNA and chromosomal DNA were cut from the dried gel and counts 
were measured. The amount of DNA internalized in the various sub-
cellular fractions was determined from the specific activity of the 32P-
labeled DNA. 
2.7. Expression of CAT gene in HepG2 cells 
HepG2 cells were grown in monolayers in 6-well plates until a 
density of 2.5 XlO5 cells. To monitor dose-dependent expression of 
CAT protein, loaded F-virosomes (0.3, 0.45, 1.2 and 3.0 mg of F-
virosomes containing 1.0, 1.5, 4.0 and 10 (ig of DNA, respectively), 
were incubated with HepG2 cells as described above. Lipofectin-medi-
ated transfection of HepG2 cells with pCIS3CAT DNA was per-
formed following a standard protocol [21]. To study time-dependent 
expression of CAT protein, F-virosomes (1.2 mg of F-virosomes con-
taining 4 |ig of pCIS3CAT DNA) were initially incubated with 
HepG2 cells for 2 h at 37°C/5% C0 2 . After 2 h of fusion, medium 
was replaced as above and cells were incubated for varying times at 
37°C/5% C0 2 . In each of the above experiments, the amount of CAT 
protein expressed per milligram of cell protein was estimated by CAT 
ELISA (as suggested by the manufacturer) taking appropriate con-
trols. 
3. Results 
3.1. Characterization of DNA loaded F-virosomes 
F-virosome preparations were examined for purity by SDS-
P A G E in the presence of (3-mercaptoethanol [14] and were 
found to be free from any detectable contamination of other 
proteins. Membrane fusion activity of these virosomal prepa-
rations was checked by their ability to lyse mouse RBCs in the 
presence of W G A [14]. F-virosome associated pCIS3CAT 
D N A was DNAase I resistant, indicating that it was en-
trapped rather than adsorbed on the virosomal membrane 
(Fig. 1). N o detectable leakage of D N A was observed from 
F-virosomes incubated with PBS or plasma/FCS and heat-
treated F-virosomes. Two to 5 ug of intact D N A was found 
to be encapsulated in 1 mg of F-virosomes. 
3.2. Uptake of pCIS3CAT DNA by HepG2 cells through 
membrane fusion and quantitation of DNA delivered to 
various subcellular fractions 
F-virosome-mediated internalization of pCIS3CAT D N A 
by cells was examined prior to checking CAT gene expression. 
After 2 h of fusion followed by 24 h of incubation of HepG2 
cells, the amount of plasmid D N A delivered by F-virosomes 
Table 1 
Specificity of F-virosome-mediated DNA delivery 
Treatment Amount of 32P-labeled DNA internalized 
(|ig)/mg of cell protein 
HepG2 cells CHO cells 
F-virosomes 0.5 0.03 
F-virosomes+2 mg/ml asialofetuin 0.04 a 
Amount of CAT protein expressed 
(pg)/mg of cell protein 
HepG2 cells CHO cells 
275.00 
30.00 
HepG2 cells and CHO cells were incubated with loaded F-virosomes (1 |xg of 32P-labeled DNA, 0.3 mg of F-protein) in the presence or absence of 
asialofetuin at the specified concentration, for 2 h at 37°C and were further incubated for 24 h as described in the text. After 24 h of incubation, cell 
extracts were assayed for radioactivity and in a parallel set of experiments, the amount of CAT protein expressed per milligram of cell protein was 
determined. The values are average of two independent determinations. 
a Not detected. 







Fig. 1. Agarose gel electrophoresis of pCIS3CAT DNA entrapped 
in F-virosomes: F-virosome sample (containing 70 ug of F-protein) 
was lysed with 2% SDS, loaded on an 0.8% agarose gel and run at 
100 V for 1 h. The bands were visualized after staining the gel with 
ethidium bromide. Lane 1: Free pCIS3CAT DNA (1 ug); Lane 2: 
Entrapped pCIS3CAT DNA before DNAase I treatment; Lane 3: 
Entrapped pCIS3CAT DNA after DNAase I treatment. 
3 DC 
< z 
(containing 1 (j.g of DNA; Fig. 2), was found to be maximum 
in the nuclear fraction. However, no radioactivity was de-
tected from the chromosomal DNA bands, thereby ruling 
out the possibility of integration of the plasmid in the host 
DNA. The amount of DNA delivered to nucleus by the cor-
responding heat-treated F-virosomes was 2 times less than 
that delivered by untreated F-virosomes. Heat-treated F-viro-
somes being fusion-inactive [16], are likely to be taken up by 
endocytosis leading to their accumulation in lysosomes. This 
results in significant degradation of pCIS3CAT DNA, as 
shown by a very low level of DNA detected in the lysoso-
mal/mitochondrial fraction (Fig. 2). The binding of F-viro-
somes to liver cells is known to be strongly inhibited in the 
presence of asialofetuin [17]. This was found to be consistent 
in our case as loaded untreated and heat-treated F-virosomes 
failed to transfer any detectable level of DNA to HepG2 cells 
preincubated with asialofetuin (Table 1). Under similar con-
ditions, loaded F-virosomes were unable to deliver pCIS3CAT 
DNA to CHO cells (Table 1) that lack the ASGP-R [22]. 
These results strongly support the target specific, fusion-medi-
ated delivery of pCIS3CAT DNA by F-virosomes and effi-
cient transport of intact DNA to the nuclear compartment 
of HepG2 cells. 
3.3. Expression of CAT gene in HepG2 cells after 
fusion-mediated DNA delivery 
The CAT gene expression in HepG2 cells was examined as a 
function of DNA dose upon fusion-mediated delivery by F-
virosomes. The maximum amount of CAT protein detected 
was achieved with 4 ug of DNA loaded in F-virosomes (Fig. 
3A). The amount of CAT protein expressed after F-virosome-
mediated delivery was 3^1 times more than that of the corre-
sponding heat controls in all doses of DNA. HepG2 cells 
preincubated with asialofetuin and CHO cells (with or with-
Fig. 2. Subcellular distribution of 32P-labeled pCIS3CAT DNA de-
livered to HepG2 cells by F-virosomes: HepG2 cells were incubated 
with F-virosomes loaded with 32P-labeled DNA and the correspond-
ing controls as described in the text. Subcellular fractions were proc-
essed for DNA isolation by Hirt lysis and were electrophoresed on 
0.8% agarose gel. The plasmid bands cut from the dried gel were as-
sayed for radioactivity. The values are mean of duplicate determina-
tions. A,B: Subcellular fractions of HepG2 cells incubated with F-
virosomes and heat-treated F-virosomes, respectively, containing 1 |xg 
of DNA. C: Subcellular fractions of HepG2 cells incubated with 
2 mg/ml asialofetuin prior to the addition of F-virosomes loaded 
with 1 ug of DNA. D: Subcellular fractions of HepG2 cells incu-
bated with 1 ug of free plasmid DNA. 
out asialofetuin preincubation), did not exhibit any detectable 
CAT expression (Table 1). In case of free DNA incubated 
with HepG2 cells and cells alone, no significant ELISA signal 
was detected (data not shown). These data suggest the tar-
geted and efficient gene expression through F-virosomes. The 
presence of serum (10% FCS) during fusion (initial 2 h incu-
bation) of loaded F-virosomes with HepG2 cells resulted in a 
modest difference in CAT expression when compared to fu-
sion in absence of serum (Table 2). It is also interesting to 
note that 1 ug of pCIS3CAT DNA delivered by the Lipofectin 
method of transfection did not express any detectable level of 
CAT protein. However, 15 ug of DNA delivered by Lipofec-
tin transfection expressed 300 pg of CAT protein which is 
comparable to the protein expressed (0.06 fg of CAT pro-
tein/cell) when 1 ug of DNA was delivered by F-virosomes 
(Fig. 3B). The amount of CAT protein expressed at varying 
times after fusion-mediated delivery of DNA was evaluated to 
check the stability of this transduction process. The amount of 
CAT protein expressed was found to be persistent till a period 
of 192 h (Fig. 4), thereby indicating the overall superior effi-
ciency of this delivery system. 
Table 2 
Effect of serum on F-virosome-mediated DNA delivery and CA T gene expression 
Treatment 
pCIS3CAT loaded F-virosomes 
CIS3CAT loaded F-virosomes (heated at 56°C, 30 min) 
Amount of CAT protein expressed (pg)/mg of cell protein 
+Serum —Serum 
440 ±38.1 533.3 ±32.8 
106.6 ± 8.0 88.0 ± 7.62 
HepG2 cells were incubated with loaded F-virosomes (containing 4 ug of DNA and 1.2 mg of F-protein) in DMEM with and without serum (10% 
FCS). The corresponding heat-treated F-virosomes were used as controls. Values represent mean (± SD) of three independent determinations. 
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Fig. 3. A: Dose-dependent expression of pCIS3CAT DNA delivered 
to HepG2 cells by F-virosomes: HepG2 cells were incubated with 
loaded F-virosomes containing varying amounts of DNA and the 
corresponding heat controls (details in the text). The amount of 
CAT protein expressed per milligram of cell protein was determined. 
Each value is mean (± SD) of three independent determinations. 
B: Comparison of F-virosome, proteo-liposome and Lipofectin-
mediated DNA delivery systems: HepG2 cells were incubated with 
untreated and heat-treated F-virosomes containing 1 |xg of pCIS3-
CAT DNA as in (A). The values are mean of duplicate determina-
tions. A,B: Amount of CAT protein expressed after delivery of 1 ug 
of DNA by F-virosomes and heat-treated F-virosomes, respectively. 
C,D: Amount of CAT protein expressed after delivery of 1 ug and 
15 ug of DNA by Lipofectin. 
novelty of avoiding the degradation of the entrapped DNA 
caused by the endocytotic pathway. We have recently estab-
lished in our laboratory that F-protein behaves both as a 
ligand and membrane fusogen for targeting of virosomal 
aqueous contents to the cytosolic compartment of liver cells 
both in vitro and in vivo [15-17]. It was shown previously that 
heat-treatment of F-protein in F-virosomes completely abro-
gates its fusogenic potential without significantly affecting the 
galactose-mediated specific recognition of ASGP-R [16]. This 
has suggested the use of heat-treated F-virosomes loaded with 
DNA, as liganded proteo-liposomes, which may be efficiently 
endocytosed by HepG2 cells. In Fig. 2, the endocytotic path-
way has been compared with that of fusion-mediated delivery 
of DNA by F-virosomes. The amount of DNA delivered to 
the nuclear compartment of HepG2 cells by fusion mode is 
appreciably more than that by heat-treated F-virosomes. This 
confirms the efficient delivery of DNA to the nucleus of 
HepG2 cells incubated with F-virosomes as compared to their 
heat-treated counterparts (Fig. 2). Considering the results 
from other appropriate controls (Fig. 2 and Table 1) of these 
experiments, the specificity and the increased efficiency of this 
DNA delivery vehicle in terms of nuclear transfer is clearly 
apprehended. Further evidence of fusion-mediated delivery of 
pCIS3CAT DNA comes from the quantitation of dose-de-
pendent (Fig. 3A) and time-dependent (Fig. 4) expression of 
CAT protein in HepG2 cells. The expression of CAT has been 
compared with that of other conventional delivery methods 
(Fig. 3A,B). The heat-treated F-virosomes are found to be 
inefficient in terms of CAT expression, presumably because 
of degradation of a major fraction of DNA in the endocytotic 
vesicles of HepG2 cells. This conforms to the DNA delivery 
process as shown in Fig. 2. Recently, adenovirus modified 
with asialoglycoprotein-polylysine conjugate was used to en-
hance targeted gene expression in liver cells through receptor-
mediated endocytosis in vitro [23]. Besides the risk of cyto-
pathic side effects of adenovirus based delivery systems (which 
4. Discussion 
The present findings constitute a rational and quantitative 
approach to targeted delivery and expression of a foreign 
reporter gene (CAT) in liver cells using a novel vehicle derived 
from Sendai viral envelopes (F-virosomes), with the added 
TIME OF INCUBATION (hours) 
Fig. 4. Kinetics of expression of pCIS3CAT DNA delivered to 
HepG2 cells by F-virosomes: HepG2 cells (2.5X 105) were incubated 
with untreated and heat-treated loaded F-virosomes containing 4 ug 
of DNA, for varying times at 37°C. At the indicated time points, 
cell extracts were prepared and CAT ELISA was performed as men-
tioned in the text. The values represent mean (± SD) of three inde-
pendent determinations. 
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limits its in vivo applications) the efficiency of the system in 
terms of transgene expression was 3-4 times less than that of 
F-virosomal delivery. The difference between the F-virosomal 
delivery system and Lipofectin-mediated transfection is more 
striking (Fig. 3B). In F-virosome mediated delivery, 1 (j,g of 
encapsulated D N A is sufficient for detectable expression of 
CAT, whereas 15 (Xg of D N A is required in the Lipofectin 
mode. HepG2 cells incubated with free pCIS3CAT D N A fail 
to express any detectable C A T protein, showing thereby the 
efficiency of this F-virosomal delivery system. In addition, the 
persistent expression of C A T protein at a significant level in 
vitro (Fig. 4) may be considered as an unique feature of this 
fusion mode of gene delivery. Moreover, serum-insensitivity 
of this delivery system in terms of CAT gene expression 
strongly supports its potential as an effective D N A carrier 
for in vivo application (Table 2). The probable reason of 
this efficient and persistent expression could be attributed to 
the delivery of large amount of functional pCIS3CAT D N A 
into the nucleus of HepG2 cells. Considering the high levels of 
C A T production achieved in vitro, we conclude that this de-
livery vehicle has immense potential for targeted delivery of 
nucleic acids of therapeutic importance in the field of gene 
therapy. 
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